NASDAQ: BJDX - Bluejay Diagnostics, Inc.

Yield per half year: +2 150%
Dividend yield: 0.00%
Sector: Healthcare

Share chart Bluejay Diagnostics, Inc.

Extended chart Simple chart
Financial Markets by TradingView

About Bluejay Diagnostics, Inc.

Bluejay Diagnostics, Inc., a medical diagnostic company, develops rapid test for the monitoring of disease progression in the United States. It is developing Symphony platform, a technology platform comprising Symphony analyzer that orchestrates blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge, which includes reagents and components. The company also offers ALLEREYE diagnostic test, a point-of-care device for the diagnosis of allergic conjunctivitis.

more details
In addition, it develops IL-6 for the monitoring of disease progression in critical care; as well as hsTNT/I and NT-proBNP for the monitoring of patients acuity with chest pain. The company was incorporated in 2015 and is headquartered in Acton, Massachusetts.
Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

IPO date 2021-11-10
ISIN US0956331039
Industry Health Care Equipment & Supplies
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.bluejaydx.com
Цена ао 3.73
Change price per day: 0% (2.34)
Change price per week: -20.68% (2.95)
Change price per month: -42.12% (4.0429)
Change price per 3 month: -30.36% (3.36)
Change price per half year: +2 150% (0.104)
Change price per year: +324.68% (0.551)
Change price per 3 year: +108.93% (1.12)
Change price per year to date: -40% (3.9)
All parameters

Underestimation

Title Value Grade
P/S 647.73 1
P/BV 0.1559 10
P/E 0 0
EV/EBITDA 0.1555 10
Total: 5.13

Efficiency

Title Value Grade
ROA, % -133.92 0
ROE, % -178.98 0
Total: 0

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Debt

Title Value Grade
Debt/EBITDA -0.0233 10
Total: 10

Growth impulse

Title Value Grade
Yield Revenue, % 0 0
Yield Ebitda, % 511.53 10
Yield EPS, % 2277.6 10
Total: 8
More

Institutions Volume Share, %
Sabby Management, LLC 149926 5.58
Armistice Capital, LLC 24230 0.9
Citadel Advisors Llc 22077 0.82
Tower Research Capital LLC (TRC) 3252 0.12
JP Morgan Chase & Company 61 0
Osaic Holdings Inc 25 0
Wells Fargo & Company 6 0



Head Job title Payment Year of birth
Mr. Indranil Dey Principal Financial, Accounting & Executive Officer, President, CEO and Director 413.16k 1963 (62 years)
Dr. Jason Cook Chief Technology Officer 278.42k 1982 (43 years)
Mr. Les DeLuca Vice President of Operations N/A
Mr. Kevin Vance Chief Commercial Officer N/A 1958 (67 years)
Mark W. Feinberg Chief Medical Advisor N/A
Dr. Mark W. Feinberg M.D. Chief Medical Advisor N/A

Address: United States, Acton. MA, 360 Massachusetts Avenue - open in Google maps, open in Yandex maps
Website: https://www.bluejaydx.com